{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:12:17Z","timestamp":1790845937973,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>The COVID\u201019 pandemic has driven an unprecedented level of global activity in drug discovery and clinical development for effective therapeutics targeting the coronavirus disease. There are currently 744 therapeutics being tested in 2879 clinical trials globally. Almost 90% of these clinical trials are focused on monotherapies. Combination therapies are the mainstay of antiviral therapeutics to increase the potency of the individual compounds and to combat the rapid evolution of resistance, although combination therapies have inherently complex clinical and regulatory development challenges. Increased understanding of the SARS\u2010CoV\u20102 lifecycle and COVID\u201019 pathology provides a scientific rationale for evaluating the effectiveness of different combinations. In this paper, we provide an overview of the current clinical trial landscape for combination therapeutics targeting COVID\u201019 through weekly scanning of national and international clinical trial registries. Our analysis delves specifically into dual combination therapies in what can be defined as \u201cpivotal clinical trials\u201d (active, randomised, controlled and at least phase II), with a focus on new and repurposed therapeutic candidates that have shown positive signals and\/or been granted authorisation for emergency use based on positive efficacy and safety data.<\/jats:p>","DOI":"10.1111\/bcp.15089","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T23:05:38Z","timestamp":1632438338000},"page":"1590-1597","source":"Crossref","is-referenced-by-count":39,"title":["Combination therapies for COVID\u201019: An overview of the clinical trials landscape"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-6426","authenticated-orcid":false,"given":"Sola","family":"Akinbolade","sequence":"first","affiliation":[{"name":"National Institute for Health Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarmuid","family":"Coughlan","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"McConkey","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC) \u2013 UK Research and Innovation (UKRI)\/University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Powell","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Excellence (NICE)  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapo","family":"Ogunbayo","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"157","article-title":"WHO declares COVID\u201019 a pandemic","volume":"91","author":"Cucinotta D","year":"2020","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","unstructured":"WillanJ KingAJ JefferyK BienzN.Challenges for NHS hospitals during covid\u201019 epidemic.2020;368:m1117.","DOI":"10.1136\/bmj.m1117"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4608"},{"key":"e_1_2_9_5_1","unstructured":"EggletonJS NagalliS.Highly Active Antiretroviral Therapy (HAART). Treasure Island FL: StatPearls Publishing;2020."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01207"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.50133"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30192-8"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1901883"},{"key":"e_1_2_9_11_1","unstructured":"National Institute for Health and Care Excellence (NICE): RAPID\u2010C19.Research to access pathway for investigational drugs for COVID\u201019 (RAPID\u2010C19).2021.https:\/\/www.nice.org.uk\/covid-19\/rapid-c19. Accessed January 28 2021."},{"key":"e_1_2_9_12_1","unstructured":"ClinicalTrials.gov.ClinicalTrials.govdatabase.2021.https:\/\/clinicaltrials.gov\/. Accessed May 17 2021."},{"key":"e_1_2_9_13_1","unstructured":"Register ECT.European Union Clinical Trials Register.2021.https:\/\/www.clinicaltrialsregister.eu\/. Accessed May 17 2021."},{"key":"e_1_2_9_14_1","unstructured":"World Health Organisation (WHO).International Clinical Trials Registry Platform (ICTRP).2021.https:\/\/ictrptest.azurewebsites.net\/Default.aspx. Accessed May 17 2021."},{"key":"e_1_2_9_15_1","unstructured":"Law Insider.Pivotal Clinical Trial definition.2021.https:\/\/www.lawinsider.com\/dictionary\/pivotal-clinical-trial. Accessed May 14 2021."},{"key":"e_1_2_9_16_1","unstructured":"NIHR Innovation Observatory (NIHRIO).COVID\u201019 Therapeutics.2021.http:\/\/www.io.nihr.ac.uk\/report\/covid-19-therapeutics\/. Accessed April 30 2021."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022926"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3869"},{"key":"e_1_2_9_21_1","unstructured":"US Food and Drug Administration (FDA).Coronavirus (COVID\u201019) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine.2020.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed May 17 2021."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_9_23_1","unstructured":"US Food and Drug Administration (FDA).FDA Approves First Treatment for COVID\u201019.2020.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19. Accessed March 3 2021."},{"key":"e_1_2_9_24_1","unstructured":"US Food and Drug Administration (FDA).Letter of Authorization: EUA for baricitinib (Olumiant) in combination with remdesivir (Veklury) for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID\u201019).2020.https:\/\/www.fda.gov\/media\/143822\/download. Accessed December 15 2020."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"e_1_2_9_26_1","unstructured":"Roche.Roche provides update on the phase III REMDACTA trial of Actemra\/RoActemra plus Veklury in patients with severe COVID\u201019 pneumonia.2021.https:\/\/www.roche.com\/media\/releases\/med-cor-2021-03-11.htm. Accessed May 17 2021."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033130"},{"key":"e_1_2_9_28_1","unstructured":"HIV i\u2010BASE.Monoclonal antibody stopped in ACTIV\u20103 study: bamlanivimab shows lack of benefit in people hospitalised with COVID\u201019.2020.https:\/\/i-base.info\/htb\/39268Accessed May 18 2021."},{"key":"e_1_2_9_29_1","unstructured":"PM Live News.Eli Lilly ends COVID\u201019 antibody trial in hospitalised setting other studies continue.2020.http:\/\/www.pmlive.com\/pharma_news\/eli_lilly_ends_covid-19_antibody_trial_in_hospitalised_setting _other_studies_continue_1354817?utm_source=pmlive&utm_medium=email&utm_campaign=pmlive_daily. Accessed March 3 2021."},{"key":"e_1_2_9_30_1","unstructured":"Takeda press release.CoVIg\u201019 Plasma Alliance Announces Topline Results from NIH\u2010Sponsored Clinical Trial of Investigational COVID\u201019 Hyperimmune Globulin Medicine.2021.https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-hyperimmune-globulin-medicine\/. Accessed August 18 2021."},{"key":"e_1_2_9_31_1","unstructured":"WCG CentreWatch.Adaptive COVID\u201019 Treatment Trial 3 (ACTT\u20103).2021.https:\/\/www.centerwatch.com\/clinical-trials\/listings\/249972\/adaptive-covid-19-treatment-trial-3-actt-3\/. Accessed May 6 2021."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2020.08.004"},{"issue":"10","key":"e_1_2_9_33_1","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID\u201019: an open\u2010label control study","volume":"6","author":"Cai Q","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00542-x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.035"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"e_1_2_9_37_1","unstructured":"US Food and Drug Administration (FDA).RE: Emergency Use Authorization 090.2021.https:\/\/www.fda.gov\/media\/147629\/download. Accessed May 18 2021."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202"},{"key":"e_1_2_9_39_1","unstructured":"US Food and Drug Administration (FDA).Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab.2021.https:\/\/www.fda.gov\/media\/145808\/download. Accessed April 28 2021."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02339-3"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.05.009"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107018"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa587"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219174"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108393"},{"key":"e_1_2_9_48_1","unstructured":"US Department of Health and Human Services.Emergency Use Authorization of Medical Products.2017.https:\/\/www.fda.gov\/media\/97321\/download. Accessed May 18 2021."},{"key":"e_1_2_9_49_1","unstructured":"US Food and Drug Administration (FDA).FDA combating COVID\u201019 with therapeutics.2020.https:\/\/www.fda.gov\/media\/136832\/download. Accessed December 10 2020."},{"key":"e_1_2_9_50_1","unstructured":"European Medicines Agency (EMA).EMA issues advice on use of REGN\u2010COV2 antibody combination (casirivimab\/imdevimab).2021.https:\/\/www.ema.europa.eu\/en\/news\/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab. Accessed May 25 2021."},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"e_1_2_9_52_1","unstructured":"US Food and Drug Administration (FDA).FDA news release: Coronavirus (COVID\u201019) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID\u201019.2020.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19. Accessed December 15 2020."},{"key":"e_1_2_9_53_1","unstructured":"National Institute of Health (NIH).Anti\u2010SARS\u2010CoV\u20102 Monoclonal Antibodies.2021.https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/. Accessed September 2 2021."},{"key":"e_1_2_9_54_1","unstructured":"US Food and Drug Administration (FDA).Emergency Use Authorization.2021.https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugs. Accessed April 28 2021."},{"key":"e_1_2_9_55_1","unstructured":"US Food and Drug Administration (FDA).Bamlanivimab and Etesevimab EUA Letter of Authorization.2021.https:\/\/www.fda.gov\/media\/145801\/download. Accessed May 18 2021."},{"key":"e_1_2_9_56_1","unstructured":"European Medicines Agency (EMA).EMA issues advice on use of antibody combination (bamlanivimab\/etesevimab).2021.https:\/\/www.ema.europa.eu\/en\/news\/ema-issues-advice-use-antibody-combination-bamlanivimab-etesevimab. Accessed April 28 2021."},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/0020731420979824"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15089","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:19:02Z","timestamp":1692991142000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/bcp.15089"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15089","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]}}}